William Holland

Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation

Christopher M. Mahaffey, Angela M. Davies, Jr Primo N. Lara et al. · Clinical Lung Cancer · 2007 · 77 citations

Schedule-dependent Apoptosis, Oncology, Medicine +8

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

Philip C. Mack, William Holland, Rebekah A. Burich et al. · Journal of Thoracic Oncology · 2009 · 66 citations · Full text

Medicine, Pathology, Plasma Are Associated +9

Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma

Christopher M. Mahaffey, Hongqiao Zhang, Alessandra Rinna et al. · Free Radical Biology and Medicine · 2009 · 63 citations · Full text

Tumor Biology, Medicine, Transcription Factor Nrf2 +9

Measurement of radical production as a result of cavitation in medical ultrasound fields

Gareth J. Price, Francis Duck, Megan Digby et al. · Ultrasonics Sonochemistry · 1997 · 48 citations

Biomedical Acoustics, Medical Ultrasound, Engineering +12

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

Matthew S Lara, William Holland, Danielle C. Chinn et al. · Clinical Lung Cancer · 2016 · 38 citations

Non–small-cell Lung Cancer, Oncology, Met Inhibitor Inc-280 +8